NCT00722917 - Efficacy and Safety of TAK-379 in Adult Subjects With Type 2 Diabetes Mellitus | Biotech Hunter

Enrollment

323

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2009

Conditions

Diabetes Mellitus

Interventions

DRUG

TAK-379

TAK-379 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks

DRUG

TAK-379

TAK-379 100 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks

DRUG

TAK-379

TAK-379 200 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks

DRUG

Pioglitazone

Pioglitazone 30 mg, tablets, orally, once daily and TAK-379 placebo-matching tablets, orally, once daily for up to 12 weeks

DRUG

Placebo

TAK-379 placebo-matching tablets, orally, and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks

Trial Locations (8)

Artesia

Norwalk

Santa Ana

Santa Monica

Panama City

Cranston

Dallas

Houston